by European Public Health Alliance | Nov 20, 2017 | Statements
According to the European Medicines Agency (EMA), “Scientific advice (SA) is when the Agency gives advice to a developer on the appropriate tests and studies in the development of a medicine. This is designed to facilitate the development and availability of...
by EPHA | Oct 5, 2017 | Statements
Brussels, 5 October 2017. The BMJ released this morning a new study titled “Availability of evidence on overall survival and quality of life benefits of cancer drugs approved by the European Medicines Agency: A retrospective cohort study of drug approvals from...
by European Public Health Alliance | Sep 27, 2017 | Statements
DOWNLOAD THE REFLECTION PAPER In 2015, the Dutch and Belgian Ministers of Health signed a historic declaration of intent to jointly negotiate with the pharmaceutical sector on the price and reimbursement of some medicines. Since then, the cooperation has been joined...
by European Public Health Alliance | Jun 9, 2017 | Opinion
Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines at the European Public Health Alliance (EPHA), discusses the latest developments in market access across Europe, and the collaborative efforts its constituents are engaging in to improve it....
